Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders

Depression and Anxiety

Volumn 12, Issue SUPPL. 1, 2000, Pages 2-19

  Ressler, Kerry J ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Depression; Norepinephrine; Pathophysiology; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; NEUROTROPHIC FACTOR; NORADRENALIN; SEROTONIN;

AFFECTIVE NEUROSIS; AMYGDALOID NUCLEUS; ANXIETY NEUROSIS; BRAIN CORTEX; BRAIN STEM; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; HYPOTHALAMUS; LIMBIC SYSTEM; NEUROANATOMY; NEURORADIOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SYMPTOMATOLOGY; THALAMUS; TREATMENT OUTCOME;

ADRENOCORTICOTROPIC HORMONE; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; BRAIN; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NERVE GROWTH FACTORS; NEURAL PATHWAYS; NEURONS; NOREPINEPHRINE; PITUITARY-ADRENAL SYSTEM; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; SEROTONIN;

EID: 0033765025     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4     Document Type: Review

References (171)

1. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder
2. Hypothalamic-pituitary-adrenal axis activity in panic disorder: Predictor of long-term outcome by pre-treatment cortisol levels
3. Metabolic rate in the amygdala predicts negative affect and depression severity in depressed patients: An FDG-PET study
4. Electrophysiology of serotonin receptor sub-types and signal transduction pathways
5. Serotonin and hallucinogens
6. Neurotransmitter transporters: Recent progress
7. Alterations in monoamine receptors in the brain of suicide victims
8. Fewer pigmented locus coeruleus neurons in suicide victims: Preliminary, results
9. The role of corticotropin-releasing factor in depression and anxiety disorders
10. 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor?
11. 2 receptors in the rat medial prefrontal cortex
12. Discharge of noradrenergic locus coeruleus neurons in behaving rats and monkeys suggests a role in vigilance
13. Afferent regulation of locus coeruleus neurons: Anatomy, physiology and pharmacology
14. The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder
15. Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
16. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in depression and in normal controls
17. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei
18. Mechanism of action of antidepressants: Monoamine hypotheses and beyond
19. Frontal and parietal metabolic disturbances in unipolar depression
20. Modulation of 5HT release in the guinea pig brain following long-term administration of antidepressant drugs
21. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications
22. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder
23. CSF serotonin: Diagnostic and seasonal differences
24. Down-regulation of β-adrenergic receptors following repeated injections of desmethylimipramine, permissive role of serotonergic axons
25. Serotonin receptors in cognitive behaviors
26. Mechanisms of emotional arousal and lasting declarative memory
27. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression
28. Presynaptic adrenergic receptor sensitivity in depression: The effect of long-term desipramine treatment
29. Monoamine dysfunction and the pathophysiology and treatment of depression
30. Serotonin and stress
31. Brain 5HT1 binding sites in depressed suicides
32. Generalized anxiety disorder: Neurobiological and pharmacotherapeutic perspectives
33. Electrophysiological characterization of adrenoceptors in the rat dorsal hippocampus I. Receptors mediating the effect of microiontophoretically applied norepinephrine
34. Anatomic and physiologic substrates of emotion in an animal model
35. Are different parts of the extended amygdala involved in fear vs. anxiety
36. A neuroendocrine study of 5HT function in depression: Evidence for biological mechanisms of endogenous and psychosocial causation
37. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
38. Role of norepinephrine in depression
39. Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin
40. Brain β-adrenoceptor binding sites in anti-depressant-free depressed suicide victims
41. Antidepressants affect amine modulation of neurotransmission in the rat hippocampal slice. Delayed effects
42. Dorsolateral prefrontal cortex dysfunction in the major psychoses: Symptom or disease specificity?
43. Neuropsychological dysfunction in depression: The relationship to regional cerebral BF
44. A functional anatomical study of unipolar depression
45. Functional anatomical differences between major depressive subtypes
46. Subgenual prefrontal cortex abnormalities in mood disorders
47. Functional neuroimaging studies of depression: The anatomy of melancholia
48. Neural plasticity to stress and antidepressant treatment
49. 3H]desipramine binding sites
50. Neurogenesis in the adult human hippocampus
51. MMPI measures of impulsivity and depression correlate with CSF 5-HIAA and HVA in depression but not schizophrenia
52. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41
53. Recovery from major depression is not associated with normalization of serotonergic function
54. Pharmacology and physiology of central noradrenergic systems
55. The role of corticotropin-releasing factor-norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress
56. Serotonin
57. Mental depression in hypertensives treated for long periods with large doses of reserpine
58. The amygdala modulates prefrontal cortex activity relative to conditioned fear
59. Serotonin receptor subtypes
60. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress
61. Neurogenesis in the neocortex of adult primates
62. Stress and hippocampal neurogenesis
63. Serotonin and hippocampal neurogenesis
64. The neurobiological basis of mixed depression-anxiety states
65. 3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain
66. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat
67. Effects of electroconvulsive shock on the scrotonin metabolism and serotonin 1A receptors in the rat brain
68. The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders
69. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans
70. Noradrenergic enhancement of long-term potentiation at mossy fiber synapses in the hippocampus
71. 5HT receptor classification and nomenclature: Toward a harmonization with the human genome
72. The time course of noradrenergic pre- and postsynaptic activity during chronic desipramine treatment
73. 3H]paroxetine binding on human platelets
74. Serotonin and behavior: A general hypothesis
75. Activity of serotonergic neurons in behaving animals
76. Effects of pharmacological agents on MHPG
77. Early childhood predictors of adult anxiety disorders
78. Altered platelet serotonin uptake kinetics in schizophrenia and depression
79. Neuronal plasticity in cat visual cortex: A proposed role for the central noradrenaline system
80. Comorbidity of DSM-IIIR major depressive disorder in the general population: Results from the US National Comorbidity Survey
81. Degeneration of locus coeruleus axons in stress-induced depression model
82. Long-term stress degenerates, but imipramine regenerates, noradrenergic axons in the rat cerebral cortex
83. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression
84. Corticotropin-releasing factor, norepinephrine, and stress
85. Mood disorders. I: Major depressive disorders
86. Emotion, motivation, and anxiety: Brain mechanisms and psychophysiology
87. 3H]-paroxetine
88. Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: Neurochemical and clinical correlates
89. Fear and the brain: Where have we been, and where are we going?
90. The role of noradrenaline in depression: A review
91. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants
92. Comparative assessment of monoamine afferents in mammalian cerebral cortex
93. Hormone responses to fenfluramine and placebo challenge in endogenous depression
94. General organization of cortical monoamine systems
95. Catecholamine metabolism, depressive illness and drug response
96. Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosin in healthy controls and in depressed patents
97. The serotonin hypothesis of major depression
98. 123I]-2 β-carbomethoxy-3 β-(4-iodophenyl) tropane and single photon emission computed tomography
99. BDNF promotes the survival and sprouting of serotonergic axons in the rat brain
100. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims
101. Blunted serotonergic responsivity in depressed patients
102. Postmortem studies of suicide victims
103. Role of the serotonergic system in the pathogenesis of major depression and suicidal behavior
104. Biochemical anatomy: Insights into the cell biology and pharmacology of the dopamine and serotonin systems in the brain
105. Serotonergic measures in suicide brain: 5-HT(1a) binding sites in frontal cortex of suicide victims
106. Effects of clonidine on growth hormone release in psychiatric patients and controls
107. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
108. Cortical pathways to the mammalian amygdala
109. Stress and hippocampal plasticity
110. 2-Adrenoceptors in the brains of suicide victims: Increased receptor density associated with major depression
111. Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: Effects of chronic stress and drug treatments
112. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments
113. Extinction of emotional learning: Contribution of medial prefrontal cortex
114. Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats
115. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients
116. 3H]imipramine binding sites in geriatric depression
117. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions
118. Psychopharmacology of affective disorders in the 21st century
119. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus
120. The functional anatomy, neurochemistry, and pharmacology of anxiety
121. D-fenfluramine-induced prolactin and cortisol release in major depression: Response to treatment
122. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behavior
123. Glial reduction in the subgenual prefrontal cortex in mood disorders
124. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims
125. 2 adrenoceptors is elevated in the locus coeruleus from victims of suicide
126. Corticotropin-releasing factor concentrations exhibit an apparent diurnal rhythm in hypothalamic and extrahypothalamic brain regions: Differential sensitivity to corticosterone
127. Role of serotonin in the pathophysiology of depression: Focus on the serotonin transporter
128. Molecular and cellular mechanisms of antidepressant drugs
129. Monoaminergic fibers form conventional synapses in the cerebral cortex
130. Desensitization of the neuronal 5HT carrier following its long-term blockade
131. Psychoneuroendocrinology of depression
132. Sources of variance in clinical studies in MHPG
133. Selective antidepressant and cerebrospinal fluid: Lack of specificity on noradrenaline and serotonin metabolism
134. Noradrenergic function in depressive disorders
135. Networks related to the orbital and medial prefrontal cortex: A substrate for emotional behavior?
136. Serotonin function and depression. Neuroendocrine and mood responses to intravenous L-tryptophan in depressed patients and healthy comparison subjects
137. Increased number of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus of depressed patients
138. Corticotropin-releasing hormone (CRH) mRNA in paraventricular nucleus of patients with Alzheimer disease or depression
139. Serotonergic modulation of neurotransmission in the rat basolateral amygdala
140. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
141. Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography
142. Role of norepinephrine in the pathophysiology and treatment of mood disorders
143. Central norepinephrine neurons and behavior
144. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test
145. Norepinephrine and its metabolites in cerebrospinal fluid, plasma and urine: Relationship to hypothalamic-pituitary-adrenal axis function in depression
146. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients
147. Recent studies on norepinephfine systems in mood disorders
148. The catecholamine hypothesis of affecdve disorders: A review of supporting evidence
149. Serotonin attenuates a slow inhibitory postsypaptic potential in rat hippocampal neurons
150. Noradrenergic function in generalized anxiety, disorder, major depressive disorder, and healthy subjects
151. Hippocampal atrophy in recurrent major depression
152. The growth hormone response to clonidine in acute and remitted depressed male patients
153. 3H] citalopram binding sites in the nonhuman primate brain
154. 2 and β-adrenoceptors in different regions of rat brain
155. Association of aggressive behavior with altered serotonergic function in patients who are not suicidal
156. Serotonin modulation of sensory inputs to the lateral amygdala: Dependency on cordcosterone
157. The noradrenergic system in pathological anxiety: A focus on panic with relevance to generalized anxiety and phobias
158. Effect of chronic treatment with tricyclic antidepressant drugs on identified brain noradrenergic and serotonergic neurons
159. The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder
160. Anatomy of the serotonergic system
161. The locus coeruleus as a site for integrating cortJcotropin-releasing factor and noradrenergic mediation of stress responses
162. Physiological and anatomical determinants of locus coeruleus discharge
163. Anatomic basis for differential regulation of the rostrolateral peri-locus coeruleus region by limbic afferents
164. Action of various antidepressant treatments reduces reactivity, of noradrenergic cyclic AMP-generation system in limbic forebrain
165. New evidence for a gating action of norepinephrine in central neuronal circuits of mammalian brain
166. Catecholamines
167. Depression and anxiety: Role of the locus coeruleus and corticotropin-releasing factor
168. Resting plasma catecholamine concentrations in patients with depression and anxiety
169. Altered emotional states in knockout mice lacking 5-HT(1a) or 5-HT(1-b) receptors